This Article Full Text Full Text (PDF) Alert me when this article is cited Alert me if a correction is posted Services Email this article to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Ullenhag, G. J. Articles by Magnusson, C. G. M. Search for Related Content PubMed PubMed Citation Articles by Ullenhag, G. J. Articles by Magnusson, C. G. M.

Induction of IgG Subclass Responses in Colorectal Carcinoma Patients Vaccinated with Recombinant Carcinoembryonic Antigen¹

Department of Oncology, Radiology, and Clinical Immunology, Section of Oncology, Uppsala University Hospital, SE-75185 Uppsala, Sweden [G. J. U.]; Department of Oncology, Cancer Centre Karolinska, Karolinska Hospital, SE-171 76 Stockholm, Sweden [G. J. U., J-E. F., H. M.]; Department of Surgery, Huddinge University Hospital, SE-14186 Huddinge, Sweden [K. S.]; and Department of Medicine, Unit of Clinical Immunology and Allergy, Karolinska Hospital and Institute, Sweden [C. G. M. M.]

There is scanty information on the IgG subclass response after vaccination against cancer antigens. The induction and development of the IgG subclass responses in 18 colorectal carcinoma patients vaccinated s.c. seven times with recombinant human carcinoembryonic antigen (rhCEA) over a 12-month period were analyzed by ELISA. The patients were followed for 3 years. Four rhCEA doses were used, and half of the patients also received granulocyte macrophage-colony stimulating factor (GM-CSF) as an adjuvant. Anti-rhCEA-specific IgG1 and IgG4 responses and, to a lesser degree, IgG2 responses were markedly enhanced by concomitant GM-CSF administration, whereas the antigen dose was of minor importance. Almost no IgG3 response was observed. A significant antibody response was noted within the first weeks for IgG1 and IgG2 but noted several months later for IgG4. The responses gradually increased by repeated immunizations and peaked around 12 months for IgG1 and a few months later for IgG2 and IgG4. A sustained but reduced response was noted for these three subclasses at 24 and 36 months. Interestingly, there was a gradual shift from a predominant IgG1 response at 6 months to an IgG4 response at 15 months. No significant change in total concentrations of the four IgG subclasses was observed comparing prevaccination concentrations with concentrations at 12 months, indicating an antigen-specific effect of GM-CSF administration on the anti-rhCEA response. The clinical significance of the individual IgG subclass antibodies for tumor response is not clear and requires additional studies.

This article has been cited by other articles:

				S. Mosolits, K. Markovic, J.-E. Frodin, L. Virving, C. G. M. Magnusson, M. Steinitz, J. Fagerberg, and H. Mellstedt Vaccination with Ep-CAM Protein or Anti-Idiotypic Antibody Induces Th1-Biased Response against MHC Class I- and II-Restricted Ep-CAM Epitopes in Colorectal Carcinoma Patients Clin. Cancer Res., August 15, 2004; 10(16): 5391 - 5402. [Abstract] [Full Text] [PDF]

				G. J. Ullenhag, J.-E. Frodin, M. Jeddi-Tehrani, K. Strigard, E. Eriksson, A. Samanci, A. Choudhury, B. Nilsson, E. D. Rossmann, S. Mosolits, et al. Durable Carcinoembryonic Antigen (CEA)-Specific Humoral and Cellular Immune Responses in Colorectal Carcinoma Patients Vaccinated with Recombinant CEA and Granulocyte/Macrophage Colony-Stimulating Factor Clin. Cancer Res., May 15, 2004; 10(10): 3273 - 3281. [Abstract] [Full Text] [PDF]

				H. Ohtani, H. Wakui, A. Komatsuda, S. Okuyama, R. Masai, N. Maki, A. Kigawa, K.-i. Sawada, and H. Imai Distribution of glomerular IgG subclass deposits in malignancy-associated membranous nephropathy Nephrol. Dial. Transplant., March 1, 2004; 19(3): 574 - 579. [Abstract] [Full Text] [PDF]